Filter By Category
Archives
Share on -
AMUVATINIB
Generic Name: AMUVATINIB
ABSTRACT -
Amuvatinib is an investigational oral multi-targeted tyrosine kinase inhibitor with activity reported against c-MET, c-RET, mutant c-KIT, PDGFR, and FLT3. It has also been studied for disruption of DNA repair through Rad51 modulation, supporting research in combination oncology regimens. It remains an investigational cancer therapy rather than a routine approved drug.
DOSAGE -
Dosage should be determined only by a qualified oncology professional.
No approved standard dosing regimen is established for routine clinical use.
Clinical-trial dosing depends on cancer type, combination regimen, treatment cycle, organ function, and toxicity.
Monitor blood counts, liver function, gastrointestinal tolerance, ECG when indicated, and tumour response.
SIDE EFFECTS–
- Possible side effects include:
- Fatigue
- Nausea
- Vomiting
- Diarrhoea
- Reduced appetite
- Rash
- Cytopenias
- Liver enzyme elevations
- Hypertension or fluid retention
- QT prolongation or cardiac effects are possible targeted-therapy concerns
- Infection risk
ALLRGIC REACTIONS–
- Hypersensitivity to amuvatinib or excipients may occur.
- Symptoms may include rash, hives, swelling, wheezing, or anaphylaxis.
- Important: Report allergic symptoms promptly to the oncology team.
DRUG INTERACTIONS–
- Use caution with strong CYP3A inhibitors or inducers.
- QT-prolonging medicines and electrolyte disturbances may increase arrhythmia risk.
- Other anticancer agents can increase cytopenias, gastrointestinal toxicity, or liver toxicity.
- Anticoagulants and antiplatelet agents require caution in thrombocytopenia.
PREAUTIONS–
- Use only under oncology supervision.
- Monitor complete blood count, liver function, electrolytes, and ECG if clinically indicated.
- Use caution in cardiac disease, hepatic impairment, infection, and poor marrow reserve.
- Pregnancy must be avoided due to potential fetal harm.
WARNINGS –
- Amuvatinib is investigational and not approved for general clinical use.
- Severe myelosuppression, liver injury, cardiac events, or infection may occur.
- Do not use outside an authorised clinical programme.
- Keep out of reach of children.
Share on -
. Developed by